Activin and Inhibin

LY3154207 is a potent, subtype selective, and orally available human dopamine D1 receptor positive allosteric modulator (PAM) with minimal allosteric agonist activity ( EC 50 =3 nM)In VitroIn HEK293 cells transiently expressing human, dog, rhesus

LY3154207 is a potent, subtype selective, and orally available human dopamine D1 receptor positive allosteric modulator (PAM) with minimal allosteric agonist activity ( EC 50 =3 nM)In VitroIn HEK293 cells transiently expressing human, dog, rhesus

LY3177833 (Example 4) is an orally active CDC7 and pMCM2 inhibitor with IC 50 values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducerIn VitroLY3177833 (10 μM: 4 days) increases SA-β-gal content in Hep3B cells. MCE has not

LY3177833 (Example 4) is an orally active CDC7 and pMCM2 inhibitor with IC 50 values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducerIn VitroLY3177833 (10 μM: 4 days) increases SA-β-gal content in Hep3B cells. MCE has not

LY3177833 (Example 4) is an orally active CDC7 and pMCM2 inhibitor with IC 50 values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducerIn VitroLY3177833 (10 μM: 4 days) increases SA-β-gal content in Hep3B cells. MCE has not

LY3177833 (Example 4) is an orally active CDC7 and pMCM2 inhibitor with IC 50 values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducerIn VitroLY3177833 (10 μM: 4 days) increases SA-β-gal content in Hep3B cells. MCE has not

LY3177833 (Example 4) is an orally active CDC7 and pMCM2 inhibitor with IC 50 values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducerIn VitroLY3177833 (10 μM: 4 days) increases SA-β-gal content in Hep3B cells. MCE has not

LY3177833 (Example 4) is an orally active CDC7 and pMCM2 inhibitor with IC 50 values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducerIn VitroLY3177833 (10 μM: 4 days) increases SA-β-gal content in Hep3B cells. MCE has not

LY3372689 (Formulaic Ia) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. LY3372689 can be used for tauopathies research, including Alzheimer’s disease.In VivoLY3372689 shows a dose-dependent change in OGA enzyme occu-pancy (EO) following a

LY3372689 (Formulaic Ia) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. LY3372689 can be used for tauopathies research, including Alzheimer’s disease.In VivoLY3372689 shows a dose-dependent change in OGA enzyme occu-pancy (EO) following a

LY3372689 (Formulaic Ia) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. LY3372689 can be used for tauopathies research, including Alzheimer’s disease.In VivoLY3372689 shows a dose-dependent change in OGA enzyme occu-pancy (EO) following a

LY3372689 (Formulaic Ia) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. LY3372689 can be used for tauopathies research, including Alzheimer’s disease.In VivoLY3372689 shows a dose-dependent change in OGA enzyme occu-pancy (EO) following a